1) Morlat P et al. "Prise en charge medicale des personnes vivant avec le VIH. Actualisation 2015 du rapport 2013" October 2015 : 43 pages.
1) ラメルテオン 承認情報 (審査報告書, 申請資料概要)
2) Prescrire Editorial Staff "Raltegravir. HIV-infected children at least 2 years of age : only after prior treatment failure" Prescrire Int 2014 ; 23 (152) : 206.
2) 薬学用語解説 日本薬学会 http://www.pharm.or.jp/dictionary/wiki.cgi?%e6%a6%82%e6%97%a5%e3%83%aa%e3%82%ba%e3%83%a0
3) Prescrire Editorial Staff "First-line antiretroviral treatment of HIVinfected children. A choice largely based on adult data" Prescrire Int 2011 ; 20 (115) : 101-104.
3) 日薬理誌 新薬紹介総説 メラトニン受容体作動薬ラメルテオンの薬理作用と臨床試験成績 平井圭介ほか https://www.jstage.jst.go.jp/article/fpj/136/1/136_1_51/_pdf/-char/ja
4) メラトニン研究の歴史 飯郷雅之 時間生物学 Vol 17 No 1 http://chronobiology.jp/journal/JSC2011-1-023.pdf
4) EMA-CHMP "Public assessment report for Isentress. EMEA/H/C/000860/X/0044/G" 26 June 2014 : 57 pages.
5) 藤井正嗣ら, 高血圧自然発症ラット (SHR) における高血圧の発症に及ぼすメラトニンの影響, 日本臨床試験生理学雑誌, 1993 : 23 (6) : 525-532
5) HAS-Commission de la transparence "Avis-Isentress 100 mg, granules pour suspension buvable" 18 November 2015 : 19 pages.
6) European Commission "uropean Commission19 pages. mber 2016 : 160 pages.
8) Markus RP, et al. Immune-Pineal Axis-Acute inflammatory responses coordinate melatoninsynthesis by pinealocytes and phagocytes. Br J Pharmacol. 2017 Nov 4 (e-pub) https://www.ncbi.nlm.nih.gov/pubmed/29105727
10) U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER) : Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf